233 related articles for article (PubMed ID: 22512587)
21. Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity.
Arlt W; Neogi P; Gross C; Miller WL
J Mol Endocrinol; 2004 Apr; 32(2):425-36. PubMed ID: 15072549
[TBL] [Abstract][Full Text] [Related]
22. Structures of PPARγ complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs.
Lee MA; Tan L; Yang H; Im YG; Im YJ
Sci Rep; 2017 Dec; 7(1):16837. PubMed ID: 29203903
[TBL] [Abstract][Full Text] [Related]
23. Thiazolidinediones: An In-Depth Study of Their Synthesis and Application to Medicinal Chemistry in the Treatment of Diabetes Mellitus.
Long N; Le Gresley A; Wren SP
ChemMedChem; 2021 Jun; 16(11):1716-1735. PubMed ID: 33844475
[TBL] [Abstract][Full Text] [Related]
24. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?
Consoli A; Formoso G
Diabetes Obes Metab; 2013 Nov; 15(11):967-77. PubMed ID: 23522285
[TBL] [Abstract][Full Text] [Related]
25. Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation.
Higgins LS; Depaoli AM
Am J Clin Nutr; 2010 Jan; 91(1):267S-272S. PubMed ID: 19906796
[TBL] [Abstract][Full Text] [Related]
26. Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
Liu W; Lau F; Liu K; Wood HB; Zhou G; Chen Y; Li Y; Akiyama TE; Castriota G; Einstein M; Wang C; McCann ME; Doebber TW; Wu M; Chang CH; McNamara L; McKeever B; Mosley RT; Berger JP; Meinke PT
J Med Chem; 2011 Dec; 54(24):8541-54. PubMed ID: 22070604
[TBL] [Abstract][Full Text] [Related]
27. [The role of peroxisome proliferator-activated receptor gamma in the pathogenesis of diabetes and atheromatosis].
Gacka M; Adamiec R; Dobosz T; Szymaniec S; Bednarska-Chabowska D
Przegl Lek; 2004; 61(12):1436-9. PubMed ID: 15850344
[TBL] [Abstract][Full Text] [Related]
28. Red wine: a source of potent ligands for peroxisome proliferator-activated receptor γ.
Zoechling A; Liebner F; Jungbauer A
Food Funct; 2011 Jan; 2(1):28-38. PubMed ID: 21773583
[TBL] [Abstract][Full Text] [Related]
29. The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis.
Feige JN; Gelman L; Rossi D; Zoete V; Métivier R; Tudor C; Anghel SI; Grosdidier A; Lathion C; Engelborghs Y; Michielin O; Wahli W; Desvergne B
J Biol Chem; 2007 Jun; 282(26):19152-66. PubMed ID: 17468099
[TBL] [Abstract][Full Text] [Related]
30. Multitargeted bioactive ligands for PPARs discovered in the last decade.
Zhang J; Liu X; Xie XB; Cheng XC; Wang RL
Chem Biol Drug Des; 2016 Nov; 88(5):635-663. PubMed ID: 27317624
[TBL] [Abstract][Full Text] [Related]
31. Ligands of the peroxisome proliferator-activated receptor-gamma and heart failure.
Thiemermann C
Br J Pharmacol; 2004 Jul; 142(6):1049-51. PubMed ID: 15303252
[TBL] [Abstract][Full Text] [Related]
32. PPAR- γ agonist in treatment of diabetes: cardiovascular safety considerations.
Abbas A; Blandon J; Rude J; Elfar A; Mukherjee D
Cardiovasc Hematol Agents Med Chem; 2012 Jun; 10(2):124-34. PubMed ID: 22471957
[TBL] [Abstract][Full Text] [Related]
33. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
[TBL] [Abstract][Full Text] [Related]
34. Structural basis for differential activities of enantiomeric PPARγ agonists: Binding of S35 to the alternate site.
Jang JY; Koh M; Bae H; An DR; Im HN; Kim HS; Yoon JY; Yoon HJ; Han BW; Park SB; Suh SW
Biochim Biophys Acta Proteins Proteom; 2017 Jun; 1865(6):674-681. PubMed ID: 28342850
[TBL] [Abstract][Full Text] [Related]
35. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
36. Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity.
Guasch L; Sala E; Valls C; Blay M; Mulero M; Arola L; Pujadas G; Garcia-Vallvé S
J Comput Aided Mol Des; 2011 Aug; 25(8):717-28. PubMed ID: 21691811
[TBL] [Abstract][Full Text] [Related]
37. Can PPARgamma agonists have a role in the management of obesity-related hypertension?
Chetty VT; Sharma AM
Vascul Pharmacol; 2006 Jul; 45(1):46-53. PubMed ID: 16713364
[TBL] [Abstract][Full Text] [Related]
38. Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes.
Gelman L; Feige JN; Desvergne B
Biochim Biophys Acta; 2007 Aug; 1771(8):1094-107. PubMed ID: 17459763
[TBL] [Abstract][Full Text] [Related]
39. Peroxisome proliferator activated receptor gamma and oxidized docosahexaenoic acids as new class of ligand.
Itoh T; Yamamoto K
Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):541-7. PubMed ID: 18193404
[TBL] [Abstract][Full Text] [Related]
40. INT131: a selective modulator of PPAR gamma.
Motani A; Wang Z; Weiszmann J; McGee LR; Lee G; Liu Q; Staunton J; Fang Z; Fuentes H; Lindstrom M; Liu J; Biermann DH; Jaen J; Walker NP; Learned RM; Chen JL; Li Y
J Mol Biol; 2009 Mar; 386(5):1301-11. PubMed ID: 19452630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
